CALGARY, April 26, 2017 /PRNewswire/ - Oncolytics
Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF) (Oncolytics or the
Company), will participate in the Bloom Burton & Co. Healthcare
Investor Conference in a session on Tuesday, May 2nd, 2017
at 1:30 pm ET. The conference takes place on May 1st
& 2nd at the Sheraton Centre Toronto Hotel, Lower Concourse
Level.
A live audio link to the webcast session will be available
at http://wsw.com/webcast/bloomburton2/oncyf and on the
company's website
at http://www.oncolyticsbiotech.com/investor-centre/presentations.
It is recommended that listeners log on 10 minutes in advance of a
live session to register and download any necessary software. An
audio replay will be accessible approximately two hours following
the presentation on the Oncolytics website.
Bloom Burton & Co. is hosting its sixth annual Healthcare
Investor Conference where they will showcase approximately 60 of
the premier Canadian healthcare companies to their network of
investors from across Canada, the
U.S. and Europe. The Conference
will have networking sessions, keynote speeches and panel
discussions with venture capital, public equity and strategic
investors. The event attracts investors who are interested in the
latest developments in Canadian healthcare companies. Investors
will have the opportunity to obtain corporate updates from
presenting companies and participate in a 1-on-1 meeting system
with company management.
About Oncolytics Biotech Inc.
Oncolytics is a
biotechnology company developing REOLYSIN, an immuno-oncology
viral-agent, as a potential treatment for a variety of tumor types.
The compound induces selective tumor lysis and promotes an inflamed
tumor phenotype through innate and adaptive immune responses to
treat a variety of cancers. Oncolytics' clinical development
program emphasizes three pillars: chemotherapy combinations to
trigger selective tumor lysis; immuno-therapy combinations to
produce adaptive immune responses; and immune modulator (IMiD)
combinations to facilitate innate immune responses.
Oncolytics is currently planning its first registration study in
breast cancer, as well as studies in combination with checkpoint
inhibitors and IMID/targeted therapies in solid and hematological
malignancies. For further information about Oncolytics,
please visit: www.oncolyticsbiotech.com.
The session and webcast times are subject to change. This
release and the presentation related thereto contain
forward-looking statements which involve known and unknown risks,
delays, uncertainties and other factors not under the Company's
control and which may cause actual results, performance or
achievements of the Company to be materially different from the
results, performance or expectations implied by these
forward-looking statements. Such risks and uncertainties include,
among others, the efficacy of REOLYSIN® as a cancer treatment, the
success and timely completion of clinical studies and trials,
uncertainties related to the research and development of
pharmaceuticals and uncertainties related to the regulatory
process. Investors should consult the Company's quarterly and
annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to
the forward-looking statements. Investors are cautioned against
placing undue reliance on forward-looking statements. The Company
does not undertake to update these forward-looking statements,
except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.